Skip to main content
Skip to footer

Unlocking Transparency of Artificial Intelligence Models in Pharmacovigilance

Tejas Almelkar

Product Manager, TCS ADD Safety, TCS

Dr. Alejandra Guerchicoff

Industry Leader – TCS ADD Safety, TCS

You have these already downloaded

We have sent you a copy of the report to your email again.

The Life Sciences (LS) industry handles large amounts of health and safety data from Research & Development, Clinical Trials, Post-marketing and Real-World Data. The volume of datasets and metadata has rapidly exceeded the capability for humans to process, handle, and review them. Despite this, LS has been slower than others to adopt and embrace AI based automation. Cognitive and intelligent platforms have a huge potential to drive safety case processing efficiencies and over time, replace the traditional PV systems. 

There are multiple reasons, factors, and challenges that can be attributed to the slow adoption rate, but in the present article we will focus our attention on “TRANSPARENCY”, a factor that explains the interpretability and explainability of AI algorithms and determinations. 

Transparency in AI models shall help understand the nature of errors, improve quality, efficiencies, human governance over machines, and facilitate corrective actions. We believe that truly transparent AI models have the ability to exponentially drive the adoption of AI/ML in pharmacovigilance. 

Transformation starts here

Learn how we can help you bring drugs to the market faster.

Talk to our experts

Find out more